XNCR NASDAQ
Xencor, Inc.
1W: +20.2%
1M: +17.1%
3M: +53.6%
YTD: +101.0%
1Y: +127.0%
3Y: +64.9%
5Y: -21.3%
$29.99
+0.81 (+2.78%)
Pre-Market: $29.77 (-0.21, -0.72%)
Weekly Expected Move ±8.0%
$21
$23
$25
$27
$29
Credit Risk of going bust: lower than 62% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 99.6%), Xencor, Inc. would be worth roughly what it owes.
Total debt $65.2M against a stock market value of $2.23B.
Distance to default 6.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $32.6M (short-term plus half of long-term), stock volatility 63.6%; Altman Z'' 0.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.12 (down 99.6%), Xencor, Inc. would be worth roughly what it owes.
Total debt $65.2M against a stock market value of $2.23B.
Distance to default 6.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $32.6M (short-term plus half of long-term), stock volatility 63.6%; Altman Z'' 0.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-07-06
Earliest Filing
2023-11-15
Latest Filing
partner: 7
investor: 3
Counterparties (Filed by XNCR)
10 relationshipsCompanies named in XNCR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Genentech, Inc. | GNE | partner | Amended and Restated Collaboration and License Agreement for royalty conversion and milestone payments | 2023-11-15 | View |
| F. Hoffmann-La Roche Ltd | — | partner | Amended and Restated Collaboration and License Agreement for royalty conversion and milestone payments | 2023-11-15 | View |
| OCM Life Sciences Portfolio LP | — | investor | Acquired royalty rights for Ultomiris and Monjuvi in exchange for upfront payments | 2023-11-07 | View |
| OMERS | — | investor | Parent entity of OCM Life Sciences Portfolio LP | 2023-11-07 | View |
| Alexion Pharmaceuticals, Inc. | — | partner | Licensor of Ultomiris® (ravulizumab) and Monjuvi®/Minjuvi® (tafasitamab-cxix) | 2023-11-07 | View |
| MorphoSys AG | — | partner | Licensor of Monjuvi®/Minjuvi® (tafasitamab-cxix) | 2023-11-07 | View |
| Incyte Inc. | INCY | partner | Co-licensor of Monjuvi®/Minjuvi® (tafasitamab-cxix) | 2023-11-07 | View |
| Janssen Biotech, Inc. | — | partner | Exclusive worldwide license and collaboration for plamotamab and CD28 bispecific antibodies | 2021-10-04 | View |
| Johnson & Johnson Innovation-JJDC, Inc. | JNJ | investor | Purchased $25 million of newly issued Xencor common stock | 2021-10-04 | View |
| Angelo Gordon Real Estate, Inc. | — | partner | Lease agreement for corporate headquarters laboratory and office space | 2021-07-06 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Earnings Release; Regulation FD; Other Events; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-29 | Material Agreement; Earnings Release; Regulation FD; Exhibits | Agreement | View |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-05-05 | Regulation FD; Exhibits | View | |
| 2026-04-27 | Officer/Director Change; Exhibits | View | |
| 2026-03-09 | Termination of Material Definitive Agreement | View | |
| 2026-03-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-31 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-04-30 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-03-13 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-03-13 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR